
Elevance Health, Inc. statistics
$429.69−0.05%Close 13 Nov 2026 · Market value $95.73B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Elevance Health, Inc. is valued at $95.73B on its latest close. Its price is 18.6 times its earnings.
| Market value | $95.73B |
|---|
| Enterprise value | $88.04B |
|---|
| Price / earnings | 18.63 |
|---|
| Price / sales | 0.47 |
|---|
| Price / book | 2.14 |
|---|
| EV / EBITDA | 12.73 |
|---|
| EV / sales | 0.44 |
|---|
| Price / free cash flow | 14.70 |
|---|
| Price / free cash flow, own 5-year average | 29.84 |
|---|
| EV / EBIT | 16.73 |
|---|
| EV / free cash flow | 13.94 |
|---|
| Free cash flow yield | 6.8% |
|---|
| Dividend yield | 1.6% |
|---|
Share price
| Latest close | $429.69 |
|---|
| Day's change | −0.0% |
|---|
| 52-week high | $450.69 |
|---|
| 52-week low | $274.84 |
|---|
| From 52-week high | −4.7% |
|---|
| Return · 1 month | +0.3% |
|---|
| Return · 3 months | +8.4% |
|---|
| Return · year to date | +22.6% |
|---|
| Return · 1 year | +31.2% |
|---|
| Beta · 1 year against the S&P 500 | 0.29 |
|---|
| 50-day average | $415.40 |
|---|
| 200-day average | $375.50 |
|---|
| RSI 14 | 54.9 |
|---|
| Average volume · 20 sessions | 1.4M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Operating margin | 3.6% |
|---|
| Net margin | 2.8% |
|---|
| Free cash flow margin | 1.6% |
|---|
| Return on equity | 13.3% |
|---|
| Return on assets | 5.1% |
|---|
| Return on invested capital | 10.1% |
|---|
| Return on invested capital, 5-year average | 12.0% |
|---|
| Return on capital employed | 9.2% |
|---|
| Stock-based compensation / revenue | 0.1% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $9.49B |
|---|
| Total debt | $32.71B |
|---|
| Net debt | −$2.67B |
|---|
| Current ratio | 1.54 |
|---|
| Quick ratio | 0.76 |
|---|
| Debt / equity | 0.75 |
|---|
| Net debt / EBITDA | −0.31 |
|---|
| Interest coverage | 5.13 |
|---|
Growth
| Revenue, latest quarter on a year | +1.4% |
|---|
| Revenue, twelve months on a year | +3.6% |
|---|
| EPS, latest quarter on a year | +17.9% |
|---|
| EPS, twelve months on a year | −3.9% |
|---|
| Revenue, 5-year compound | +10.3% |
|---|
| Revenue, 10-year compound | +9.7% |
|---|
| Net income, 5-year compound | +4.4% |
|---|
| Free cash flow, 5-year compound | −20.0% |
|---|
| EPS, 5-year compound | +7.0% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 225M |
|---|
| Shares outstanding, 5-year compound | −2.5% |
|---|
| Net share repurchases | $2.55B |
|---|
| Dividend payout | 27.0% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $1.05B |
|---|
| Effective tax rate | 15.6% |
|---|
ELV in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.